These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25989713)

  • 21. Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand.
    Permsuwan U; Chaiyakunapruk N; Dilokthornsakul P; Thavorn K; Saokaew S
    Appl Health Econ Health Policy; 2016 Jun; 14(3):281-92. PubMed ID: 26961276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK.
    Roze S; Valentine WJ; Zakrzewska KE; Palmer AJ
    Diabet Med; 2005 Sep; 22(9):1239-45. PubMed ID: 16108855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes.
    Valentine WJ; Pollock RF; Plun-Favreau J; White J
    Curr Med Res Opin; 2010 Jun; 26(6):1399-412. PubMed ID: 20387997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A UK analysis of the cost-effectiveness of Humalog Mix75/25 and Mix50/50 versus long-acting basal insulin.
    Pollock RF; Curtis BH; Smith-Palmer J; Valentine WJ
    Adv Ther; 2012 Dec; 29(12):1051-66. PubMed ID: 23179373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries.
    Gschwend MH; Aagren M; Valentine WJ
    J Med Econ; 2009 Jun; 12(2):114-23. PubMed ID: 19545216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
    Ericsson Å; Pollock RF; Hunt B; Valentine WJ
    J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy.
    Ren H; Berry S; Malkin SJP; Hunt B; Bain S
    BMJ Open; 2023 Sep; 13(9):e070473. PubMed ID: 37775297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK.
    Palmer AJ; Valentine WJ; Ray JA; Foos V; Lurati F; Smith I; Lammert M; Roze S
    Curr Med Res Opin; 2007 Apr; 23(4):895-901. PubMed ID: 17407646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
    Gao L; Zhao FL; Li SC
    Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
    CDC Diabetes Cost-effectiveness Group
    JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of switching patients with type 2 diabetes from insulin glargine to insulin detemir in Chinese setting: a health economic model based on the PREDICTIVE study.
    Yang L; Christensen T; Sun F; Chang J
    Value Health; 2012; 15(1 Suppl):S56-9. PubMed ID: 22265068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).
    Clarke P; Gray A; Adler A; Stevens R; Raikou M; Cull C; Stratton I; Holman R;
    Diabetologia; 2001 Mar; 44(3):298-304. PubMed ID: 11317659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia.
    Ali M; White J; Lee CH; Palmer JL; Smith-Palmer J; Fakhoury W; Valentine WJ
    J Med Econ; 2008; 11(4):651-70. PubMed ID: 19450074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.
    Pollock RF; Tikkanen CK
    J Med Econ; 2017 Mar; 20(3):213-220. PubMed ID: 27705031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive.
    Valentine WJ; Tucker D; Palmer AJ; Minshall ME; Foos V; Silberman C;
    Value Health; 2009; 12(1):1-9. PubMed ID: 18657104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study.
    Holden SE; Morgan CL; Qiao Q; Jenkins-Jones S; Berni ER; Currie CJ
    Diabetes Obes Metab; 2017 Aug; 19(8):1097-1105. PubMed ID: 28218819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK.
    Viljoen A; Chubb B; Malkin SJP; Berry S; Hunt B; Bain SC
    Eur J Health Econ; 2023 Aug; 24(6):895-907. PubMed ID: 36114904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
    Viriato D; Calado F; Gruenberger JB; Ong SH; Carvalho D; Silva-Nunes J; Johal S; Viana R
    J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of a novel hybrid closed-loop system compared with continuous subcutaneous insulin infusion in people with type 1 diabetes in the UK.
    Roze S; Buompensiere MI; Ozdemir Z; de Portu S; Cohen O
    J Med Econ; 2021; 24(1):883-890. PubMed ID: 34098834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.